Navigation Links
Perrigo Reports Record Revenue and Adjusted Earnings
Date:5/7/2013

ALLEGAN, Mich., May 7, 2013 /PRNewswire/ -- Perrigo Company (Nasdaq: PRGO; TASE: PRGO) today announced results for its third quarter ended March 30, 2013.

(Logo: http://photos.prnewswire.com/prnh/20120301/DE62255LOGO )

Perrigo's Chairman and CEO Joseph C. Papa commented, "We are very pleased with our performance, as the team delivered all-time record quarterly revenue and adjusted diluted earnings per share. It was a very busy quarter for the team. We signed and closed the acquisition of Rosemont Pharmaceuticals, a specialty and generic prescription pharmaceutical company focused on the manufacturing and marketing of oral liquid formulations. We shipped Guaifenesin 600mg Extended-Release tablets with $135 million in branded sales. It is the first product that is generically equivalent to Mucinex® 600mg Extended-Release tablets. We launched the generic equivalents of Luxiq® Foam and Nicorette® mini lozenges and the authorized generic of Acetadote® injection. Finally, we filed an ANDA for the generic equivalent of Androgel® 1.62% and we believe we are the first to file. After the quarter ended, we closed our acquisition of Velcera, further expanding our recent entry into companion animal health and broadening our product offering. All of these great milestones were achieved while expanding margins in a record sales quarter." 

Refer to Table I at the end of this press release for adjustments in the current year and prior year periods and additional non-GAAP information. The Company's reported results are summarized in the attached Condensed Consolidated Statements of Income, Balance Sheets and Cash Flows.

  

Perrigo Company(in thousands, except per share amounts)(see the attached Tables I and IV for reconciliation to GAAP numbers
'/>"/>

SOURCE Perrigo Company
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related medicine technology :

1. Perrigo Company To Release Third Quarter Fiscal Year 2013 Results On May 7, 2013
2. Perrigo Company To Present At The Barclays Global Healthcare Conference
3. Perrigo Company To Present At The RBC Global Healthcare Conference
4. Perrigo Confirms First to File Patent Challenge for Generic Version of Testosterone Gel 1.62%
5. Perrigo Company To Present At The Leerink Swann Global Healthcare Conference
6. Perrigo Company Acquires U.K.-based Rosemont Pharmaceuticals Ltd. For Approximately £180 Million Or $283 Million
7. Perrigo Confirms FDA Approval For Testosterone Gel 1%
8. Perrigo Reports Record Second Quarter Revenue, Adjusted Earnings and Operating Cash Flow
9. Perrigo Company To Acquire OTC Companion Animal Health Company, Velcera, Inc., For $160 Million
10. Perrigo Commences Launch Of Clobetasol Emulsion Propionate Foam, 0.05%
11. Perrigo Company To Release Second Quarter Fiscal Year 2013 Results On February 1, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... N.Y. , Jan. 23, 2015  Lixte Biotechnology Holdings, Inc. ... its Phase I trial of Lixte,s lead compound, LB‑100, is ... John S. Kovach , M.D., the founder ... planned to be completed at a single site. Accrual of ...
(Date:1/23/2015)... JUNCTION, N.J. , Jan. 23, 2015  CytoSorbents ... company commercializing its CytoSorb® extracorporeal cytokine adsorber to ... patients, announced the receipt of $385,642, net of ... participant of the Technology Business Tax Certificate Transfer ...
(Date:1/23/2015)... and BOSTON , January 23, 2015 ... discovery and development company, is delighted to announce that the ... awarded to Miles Congreve (Vice President of Chemistry), ... Malcolm Weir (Chief Executive Officer and co-founder) for ...
Breaking Medicine Technology:Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 2Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 4
... at 8 am versus placebo: - 25,/ - ... Blood pressure reduction dependent on vaccine dose and ... today at the Seventeenth European,Meeting on Hypertension in ... Italy, June 17, 2007 -,Cytos Biotechnology AG (SWX:CYTN) ...
... WIRE)--Jun 18, 2007 - Advanced Viral,Research Corp. ... today that preliminary findings from its ongoing,Phase ... AVR118,appears to have clinical activity in reducing ... dermatologic,dermabrasion., The Phase II open label dermatological ...
Cached Medicine Technology:Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur 2Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur 3Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur 4Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur 5Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur 6Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur 7Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur 8Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur 9Advanced Viral Research Corp. Announces Positive Preliminary,Findings from Ongoing Phase II Dermatological Study 2
(Date:1/22/2015)... January 22, 2015 Four years since the release ... which coincided with the marriage of Avasa & Matthew Love – ... which is scheduled for release through White Swan Records on February ... there is a sacred path available to all of us to ...
(Date:1/22/2015)... Mass. (PRWEB) January 22, 2015 EBSCO ... (AMA) are expanding their relationship in an effort to ... around the world. While EBSCO has long made AMA journals ... a sales agent for The JAMA Network. , ...
(Date:1/22/2015)... JJsHouse.com is a famous dress online store for ... its latest collection of wedding dresses , and launches ... is the wedding dress on your big day; the wedding ... Every bride wants to find the most suitable wedding dress. ...
(Date:1/22/2015)... Lower-Auto-Insurance.com has released a new blog post explaining the ... reducing the costs of an auto insurance policy . ... get lower prices for their vehicle insurance policies. The safety a ... policy costs. Because of this, drivers should always carry a ...
(Date:1/22/2015)... 22, 2015 State Forestry Institute of ... system with support from GEOSYSTEMS, a dedicated Hexagon Geospatial ... will leverage Hexagon Geospatial’s ERDAS APOLLO for ... well as point clouds and documents. This effort will ...
Breaking Medicine News(10 mins):Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4Health News:Find The Most Suitable Wedding Dress At JJsHouse.com 2Health News:Driving Safe And Other Factors That Make Auto Insurance Affordable! 2Health News:State Forestry Institute Mecklenburg-Vorpommern, Germany Embraces Hexagon Geospatial Technology 2Health News:State Forestry Institute Mecklenburg-Vorpommern, Germany Embraces Hexagon Geospatial Technology 3
... grant support, investigators at Nationwide Children,s Hospital plan to ... leads to the development of a devastating brain tumor, ... Center for Childhood Cancer at The Research Institute at ... the Matthew Larson Foundation for this research. ...
... 1 (HealthDay News) -- Screening college athletes for heart conditions ... sudden cardiac death, according to a new study. ... heart abnormality or symptoms that required further screening, prompting researchers ... in sports. Every year in the United States, 60 ...
... Gardner HealthDay Reporter , WEDNESDAY, June 1 ... researchers were able to find previously undetected changes in ... had been diagnosed with mild brain injuries sustained from ... "absolutely not there yet," Christine Mac Donald, lead author ...
... a newer, more precise form of radiation therapy, ... hormone therapy than using three-dimensional radiation therapy, according ... of the International Journal of Radiation OncologyBiologyPhysics ... Society for Radiation Oncology (ASTRO). Three-dimensional radiation ...
... -- Newly diagnosed cancer patients frequently face hurdles in ... to new research from the Perelman School of Medicine ... Saturday, June 4 at the 2011 annual meeting of ... with private health insurance had difficulty scheduling an appointment, ...
... MAYWOOD, Ill. -- Baseline concussion tests given to hundreds ... some cases, according to a Loyola University Health System ... rate, meaning a test shows an athlete has recovered, ... cognitive impairments from the concussion. This could increase risks ...
Cached Medicine News:Health News:New grant to study how pediatric brain tumor, ependymoma, develops 2Health News: Experts Recommend Cardiac Screening for College Athletes 2Health News:Hi-Tech Scan Detects Soldiers' Head Injuries 2Health News:Hi-Tech Scan Detects Soldiers' Head Injuries 3Health News:Two-thirds of newly diagnosed cancer patients unable to obtain oncology appointments 2Health News:Does baseline concussion testing really reduce risks to athletes? 2
4 mm wide tip....
Double-ended. Blunt and semi sharp 5 mm tips. Designated most popular model or size....
Double-ended. Designated most popular model or size....
Designated most popular model or size. Double-ended. 2 mm wide....
Medicine Products: